Tolerability of amodiaquine and sulphadoxine‐pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults
暂无分享,去创建一个
C. Karema | U. d’Alessandro | C. Fanello | W. van Doren | Caterina I. Fanello | Claude E. Rwagacondo
[1] P. Rosenthal,et al. Artemisinin versus Nonartemisinin Combination Therapy for Uncomplicated Malaria: Randomized Clinical Trials from Four Sites in Uganda , 2005, PLoS medicine.
[2] A. Oduro,et al. A randomized comparative study of chloroquine, amodiaquine and sulphadoxine–pyrimethamine for the treatment of uncomplicated malaria in Ghana , 2005, Tropical medicine & international health : TM & IH.
[3] C. Karema,et al. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria , 2004, Tropical medicine & international health : TM & IH.
[4] C. Karema,et al. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. , 2003, The American journal of tropical medicine and hygiene.
[5] P. Olliaro,et al. Amodiaquine for treating malaria. , 2003, The Cochrane database of systematic reviews.
[6] P. Rosenthal,et al. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial , 2001, The Lancet.
[7] P. Garner,et al. Systematic review of amodiaquine treatment in uncomplicated malaria , 1996, The Lancet.
[8] N. Kitteringham,et al. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. , 1992, Biochemical pharmacology.
[9] P. Phillips-Howard,et al. Serious Adverse Drug Reactions to Pyrimethamine-Sulphadoxine, Pyrimethamine-Dapsone and to Amodiaquine in Britain , 1990, Journal of the Royal Society of Medicine.
[10] N. Kitteringham,et al. Drug-protein conjugates--XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. , 1988, Biochemical pharmacology.
[11] N. Ratliff,et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. , 1987, The American journal of medicine.
[12] K. Neftel,et al. Amodiaquine induced agranulocytosis and liver damage. , 1986, British medical journal.
[13] G. Edwards,et al. FREQUENCY OF SEVERE NEUTROPENIA ASSOCIATED WITH AMODIAQUINE PROPHYLAXIS AGAINST MALARIA , 1986, The Lancet.
[14] R. Snow,et al. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .
[15] P. Ringwald,et al. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. , 2002, Bulletin of the World Health Organization.
[16] N. Kitteringham,et al. Immunogenicity of amodiaquine in the rat. , 1990, International archives of allergy and applied immunology.